MorNuCo, Inc.

Established 2011
Key Personnel

Dr. D. James Morre, Founder

Dr. Dorothy Morre, Founder

Nick Miner, CEO

Dr. David Taggart, Director of Research

Dr. James Kim, COO

David Gilmartin, Operations Manager

Dr. Mohammed Zaroura, Senior Laboratory Director

Dr. Maxime Gallant, Director of Special Project


1201 Cumberland Avenue

Suite B

West Lafayette, Indiana  47906



MorNuCo's program of technology development is focused on innovative solutions to cardiovascular, neurodegenerative and aging related diseases with emphasis on cancer. Our approach is to detect early before the disease progresses and to begin safe and effective treatment well in advance of life-threatening symptoms.


MorNuCo, founded in October 2011 by Professors Emeriti D. James Morré and Dorothy M. Morré, is located in Purdue Research Park, West Lafayette, Indiana. MorNuCo's technology and ongoing development is focused on a family of cell-surface ECTO-NOX (ENOX) proteins with therapeutic and diagnostic potential for the principle disorders of aging with emphasis on cancer, as well as cardiovascular and neurodegenerative diseases.

Our principal service, the ONCOblot Cancer Test was invented by MorNuCo's founders and first became commercially available in 2013. This test detects ENOX2 protein originating from 20 different tissues of origin. The test detects and distinguishes among the tissues of origin of 26 cancer types as early as stage 0. ONCOblot® is a Laboratory Developed Test that is CLIA registered and accredited by the College of American Pathologists. 

Kurz Purdue Technology Center, 1281 Win Hentschel Blvd., West Lafayette, IN 47906; 765-588-3470

© 2016 Purdue Research Foundation | Maintained by Purdue Research Foundation

Trouble with this page? Please contact Purdue Research Foundation by phone, 765-588-3470, or fax, 765-463-3501.